A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma

BACKGROUND: Both the epidermal growth factor receptor and vascular endothelial growth factor pathways are frequently overexpressed in glioblastoma multiforme. This study combined bevacizumab, a vascular endothelial growth factor inhibitor, and erlotinib, an epidermal growth factor receptor inhibitor...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Clarke, Jennifer L., Molinaro, Annette M., Phillips, Joanna J., Butowski, Nicholas A., Chang, Susan M., Perry, Arie, Costello, Joseph F., DeSilva, Ashley A., Rabbitt, Jane E., Prados, Michael D.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2014
Onderwerpen:
Clinical Investigations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4057142/
https://ncbi.nlm.nih.gov/pubmed/24637230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou029
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items